Cannabidiol and other Cannabinoids
Cannabidiol (CBD) is a non-psychotropic constituent of Cannabis sativa that has grown in popularity during the last decade. CBD is the active component of EPIDIOLEX®, a U.S. Food and Drug Administration (FDA)-approved drug designed for the treatment of drug-resistant pediatric epileptic seizures associated with several rare syndromes. Furthermore, CBD has been proposed as a treatment for a number of other diseases for which clinical trials are now ongoing.
Accumulating evidence indicates that the number of “CBD-containing” products, available mostly online, is growing exponentially. However, the U.S. FDA currently prohibits sales of CBD as a dietary supplement (DS) or ingredient in conventional food. Further, clear federal regulatory and quality oversight does not exist, which has led to an uncontrolled CBD market that, in turn, threatens to result in negative health effects experienced by a trusting public.
Thus, there are open questions demanding answers in the very near future: For which medical purposes is CBD provably effective? Can it be used safely as a non-prescription product? At what level? Is a hemp extract that contains CBD a different ingredient than isolated CBD? Is CBD safe for everyone? What is a future path for hemp products with CBD as well as for other cannabinoids? Should CBD be allowed as a drug only, or is there a way for hemp extracts to be listed as a dietary supplement and food ingredient?
Information about the Guest Editors
Igor Koturbash, MD, PhD is an Associate Professor and an Interim Chair at the Department of Environmental and Occupational Health, and the Founder and Co-Director of the Center for Dietary Supplements Research at the Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences (Little Rock, AR). Igor has a long-lasting interest in diet and dietary supplements and their impact on human health. Therefore, the major focus of his research is safety, efficacy and mechanisms of action of dietary supplements and understanding how diet and dietary supplements can modulate tissue response to cancer therapy.
Douglas ‘Duffy’ MacKay
Douglas ‘Duffy’ MacKay, N.D., is Senior Vice President, Scientific & Regulatory Affairs for CV Sciences, Inc., makers of PlusCBD™ where he is responsible for scientific innovation and regulatory compliance. Dr. MacKay came to CV Sciences after a 10-year career with the Council for Responsible Nutrition in Washington, D.C., where he served as a Senior VP, ensuring that the association’s scientific, policy and legislative positions were based on credible scientific rationale. Dr. MacKay is a member of the CRN Board of Directors, American Botanical Council (ABC) Advisory Board, and FDLI Cannabis-Derived Products Committee. In addition, he volunteers on several scientific journal editorial boards.